Who founded Rejuvenation Technologies Inc.?

Rejuvenation Technologies Inc. was founded by Glenn Markov, John Ramunas in 2016.

Who are Rejuvenation Technologies Inc.'s investors?

Rejuvenation Technologies Inc.'s investors include Asymmetry Ventures, Startups, Y Combinator.

Where is Rejuvenation Technologies Inc. headquartered?

Rejuvenation Technologies Inc. is headquartered in San Francisco, US.

Rejuvenation Technologies Inc.

San Francisco, US · Founded 2016 · 2 employees · 3 known investors

Rejuvenation develops proprietary mRNA and lipid nanoparticle technology to safely lengthen telomeres in human cells, targeting cellular aging and diseases caused by short telomeres including pulmonary fibrosis, liver disease, and bone marrow failure.

Also known as Rejuvenation Technologies

Biotech Deep Tech Healthtech Longevity Anti-Aging Gene Therapy NanomedicineUnited States of AmericaAmerica / CanadaPartly Remote

Founders & leadership· Y Combinator alumni (S18)

Rejuvenation Technologies Inc. was founded in 2016 by Glenn Markov and John Ramunas.

Glenn Markov inCo-founder · Chief Operating OfficerGlenn Markov holds a PhD in Genetics from Stanford, which he completed in 2018.

John Ramunas inCo-Founder, CEOJohn Ramunas holds a PhD and conducted telomere research at Stanford in Helen Blau's lab; he is founder of Rejuvenation Technologies, which is developing mRNA-based telomere extension and has received FDA INTERACT clearance, Khosla Ventures seed funding, and admission to Y Combinator.

Investors · 3

Asymmetry VenturesRichmond · $125K – $500Kvia Rob Ness · inferred

StartupsCdmxvia Alejandro Gálvez · inferred

Y CombinatorSan Francisco · $500K

Competitors · 3

by search overlap

Rejuvenate Bio10 shared keywordsRejuvenate Bio develops gene therapy treatments aimed at the root causes of aging to address chronic, age-related conditions such as osteoarthritis, heart disease, and cancer. It targets both companion animals (particularly dogs) and humans.

Lifespan6 shared keywordsLifespan.io publishes news, research roundups, and advocacy content focused on longevity and rejuvenation therapies aimed at extending healthy lifespan. It covers developments across research, treatment, and policy related to aging.

Read on Scientific American5 shared keywordsScientific American is a science and technology news publication covering research, discoveries, and developments across fields such as astronomy, biology, physics, health, and climate. It publishes articles, magazine issues, discussions, and organizes reader travel experiences and editorial features.

Companies competing with Rejuvenation Technologies Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 3 SBIR/STTR awards

Federal grants — no equity taken

Agency	Phase	Year	Amount
National Institutes of Health (NIH)National Institutes of Health	Phase II	2023	$626.7K
National Institutes of Health (NIH)National Institutes of Health	Phase I	2022	$300K
National Institutes of Health (NIH)National Institutes of Health	Phase ISTTR	2020	$272.4K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Rejuvenation Technologies Inc. do?: Rejuvenation develops proprietary mRNA and lipid nanoparticle technology to safely lengthen telomeres in human cells, targeting cellular aging and diseases caused by short telomeres including pulmonary fibrosis, liver disease, and bone marrow failure.
Who founded Rejuvenation Technologies Inc.?: Rejuvenation Technologies Inc. was founded by Glenn Markov, John Ramunas in 2016.
Who are Rejuvenation Technologies Inc.'s investors?: Rejuvenation Technologies Inc.'s investors include Asymmetry Ventures, Startups, Y Combinator.
Where is Rejuvenation Technologies Inc. headquartered?: Rejuvenation Technologies Inc. is headquartered in San Francisco, US.